This module is part of the Series “The Immunological Basis for Immunization”, which was
initially developed in 1993 as a set of eight modules focusing on the vaccines included in …

Haemophilus influenzae type b (Hib) is a major cause of serious infections in childhood.
New vaccines have been developed which are effective in invoking immunity against this …

On August 30-31, 1982, the National Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH), sponsored a workshop to review the status of …

Following the reduction in efficacy of Hib-TT vaccines in the primary immunization schedule
observed in the UK between 1999 and 2003, batches of vaccine manufactured by two …

The infant rat model for Haemophilus influenzae type b (Hib) disease was modified to test
the protective efficacy of candidate vaccines. The administration of 0.4 micrograms of …

Haemophilus influenzae, a major cause of meningitis in young children leading to death and
other neurological sequelae. The disease leaves 15 to 35% of the survivors with permanent …

The immunogenicity, efficacy, adverse effects, dosage recommendations, and cost of the
three commercially available Haemophilus influenzae type b (Hib) conjugate vaccines are …

Haemophilus influenzae (Hi) is responsible for significant morbidity and mortality worldwide,
particularly in children under 5 years of age. In the pre-vaccine era, 95% of serious disease …

Progress in Vaccination against Haemophilus influenzae type b in the Americas | PLOS
Medicine Skip to main content Advertisement PLOS Medicine Browse Current Issue Journal …

Srinivas Acharya Nanduri, Andrea R. Sutherland, Lance K. Gordon, and Mathuram
Santosham than 5 years of age, 8 and that older children and adults had naturally acquired …